0 65

Cited 0 times in

Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer

DC FieldValueLanguage
dc.contributor.author최서희-
dc.contributor.author장지석-
dc.contributor.author구자승-
dc.contributor.author손주혁-
dc.contributor.author금기창-
dc.contributor.author서창옥-
dc.contributor.author김용배-
dc.date2018-11-
dc.date.accessioned2021-01-04T02:20:18Z-
dc.date.available2021-01-04T02:20:18Z-
dc.date.issued2018-11-
dc.identifier.issn0277-3732-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/181201-
dc.description.abstractObjectives: Triple-negative breast cancers (TNBC) is an aggressive disease and often associated with early distant metastases, which negate the role of adjuvant radiotherapy. We studied the clinical utility of programmed death ligand-1 (PD-L1) and other available factors in predicting clinical outcome in TNBC. Methods: Of the 539 patients with newly diagnosed TNBC between 2004 and 2011, we analyzed 117 patients who had both tumor samples which PD-L1 protein expression could be evaluated using immunohistochemistry and initial staging F-fluorodeoxyglucose (FDG) positron emission tomography (PET) data to find available immunologic or metabolic factors. Median follow-up duration was 53 months. Results: Strong PD-L1 expression was significantly associated with increased risk of recurrence along with tumor hypermetabolism. The systemic recurrence rate was significantly higher in the strong PD-L1 group than the weak PD-L1 group (35% vs. 11%; P=0.002); whereas there was no difference in locoregional failures (8% vs. 8%). Meanwhile, tumor hypermetabolism seemed to relate with an increase in overall recurrences (26% vs. 8%; P=0.019), not with specific type (locoregional, 9% vs. 3% [P=0.289]; systemic, 22% vs. 8% [P=0.051]). The relationship between PD-L1 expression and survival outcomes retained significance even after adjusting potential risk factors. Conclusions: PD-L1 and tumor metabolism might have role of predicting an increase in treatment failures. Especially, strong PD-L1 expression status was related to distant metastasis-dominant recurrence pattern which needs for intensive systemic therapy.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherLippincott Williams & Wilkins-
dc.relation.isPartOfAMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleDifferential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학교실)-
dc.contributor.googleauthorSeo Hee Choi-
dc.contributor.googleauthorJee Suk Chang-
dc.contributor.googleauthorJa Seung Koo-
dc.contributor.googleauthorJong Won Park-
dc.contributor.googleauthorJoo Hyuk Sohn-
dc.contributor.googleauthorKi Chang Keum-
dc.contributor.googleauthorChang-Ok Suh-
dc.contributor.googleauthorYong Bae Kim-
dc.identifier.doi10.1097/COC.0000000000000426-
dc.contributor.localIdA04867-
dc.contributor.localIdA04658-
dc.contributor.localIdA04658-
dc.contributor.localIdA00198-
dc.contributor.localIdA00198-
dc.contributor.localIdA01995-
dc.contributor.localIdA01995-
dc.contributor.localIdA00272-
dc.contributor.localIdA00272-
dc.contributor.localIdA01919-
dc.contributor.localIdA01919-
dc.contributor.localIdA00744-
dc.contributor.localIdA00744-
dc.relation.journalcodeJ00075-
dc.identifier.eissn1537-453X-
dc.identifier.pmid29419531-
dc.identifier.urlhttps://journals.lww.com/amjclinicaloncology/toc/9000/00000-
dc.contributor.alternativeNameChoi, Seo Hee-
dc.contributor.affiliatedAuthor최서희-
dc.contributor.affiliatedAuthor장지석-
dc.contributor.affiliatedAuthor장지석-
dc.contributor.affiliatedAuthor구자승-
dc.contributor.affiliatedAuthor구자승-
dc.contributor.affiliatedAuthor손주혁-
dc.contributor.affiliatedAuthor손주혁-
dc.contributor.affiliatedAuthor금기창-
dc.contributor.affiliatedAuthor금기창-
dc.contributor.affiliatedAuthor서창옥-
dc.contributor.affiliatedAuthor서창옥-
dc.contributor.affiliatedAuthor김용배-
dc.contributor.affiliatedAuthor김용배-
dc.citation.volume41-
dc.citation.number11-
dc.citation.startPage1049-
dc.citation.endPage1057-
dc.identifier.bibliographicCitationAMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, Vol.41(11) : 1049-1057, 2018-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.